52 related articles for article (PubMed ID: 10928046)
21. Non-invasive assessment of tumour cell proliferation with positron emission tomography and [76Br]bromodeoxyuridine.
Böni R; Bläuenstein P; Dummer R; von Schulthess GK; Schubiger PA; Steinert HC
Melanoma Res; 1999 Dec; 9(6):569-73. PubMed ID: 10661767
[TBL] [Abstract][Full Text] [Related]
22. Elimination of nonspecific radioactivity from [76Br]bromide in PET study with [76Br]bromodeoxyuridine.
Lu L; Bergström M; Fasth KJ; Wu F; Eriksson B; Långström B
Nucl Med Biol; 1999 Oct; 26(7):795-802. PubMed ID: 10628559
[TBL] [Abstract][Full Text] [Related]
23. [76Br]Bromodeoxyuridine, a potential tracer for the measurement of cell proliferation by positron emission tomography, in vitro and in vivo studies in mice.
Ryser JE; Bläuenstein P; Rémy N; Weinreich R; Hasler PH; Novak-Hofer I; Schubiger PA
Nucl Med Biol; 1999 Aug; 26(6):673-9. PubMed ID: 10587106
[TBL] [Abstract][Full Text] [Related]
24. Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.
Cervantes-Madrid D; Romero Y; Dueñas-González A
Biomed Res Int; 2015; 2015():690492. PubMed ID: 26425550
[TBL] [Abstract][Full Text] [Related]
25. [76Br]Bromodeoxyuridine PET in tumor-bearing animals.
Gardelle O; Roelcke U; Vontobel P; Crompton NE; Guenther I; Bläuenstein P; Schubiger AP; Blattmann H; Ryser JE; Leenders KL; Kaser-Hotz B
Nucl Med Biol; 2001 Jan; 28(1):51-7. PubMed ID: 11182564
[TBL] [Abstract][Full Text] [Related]
26. Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?
Gazdar AF; Gao B; Minna JD
Lung Cancer; 2010 Jun; 68(3):309-18. PubMed ID: 20079948
[TBL] [Abstract][Full Text] [Related]
27. [PET in the diagnosis and treatment of lung cancer].
Wang Y; Zhou Q
Zhongguo Fei Ai Za Zhi; 2003 Dec; 6(6):418-22. PubMed ID: 21310122
[No Abstract] [Full Text] [Related]
28. Yrast transition strengths in 76Br.
Buccino SG; Durham FE; Holcomb JW; Johnson TD; Cottle PD; Tabor SL
Phys Rev C Nucl Phys; 1990 May; 41(5):2056-2061. PubMed ID: 9966570
[No Abstract] [Full Text] [Related]
29. High-spin states in 76Br.
Winchell DF; Saladin JX; Kaplan MS; Takai H
Phys Rev C Nucl Phys; 1990 Mar; 41(3):1264-1267. PubMed ID: 9966467
[No Abstract] [Full Text] [Related]
30. The role of DNA synthesis imaging in cancer in the era of targeted therapeutics.
Nimmagadda S; Shields AF
Cancer Metastasis Rev; 2008 Dec; 27(4):575-87. PubMed ID: 18512023
[TBL] [Abstract][Full Text] [Related]
31. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives.
Nestle U; Kremp S; Grosu AL
Radiother Oncol; 2006 Nov; 81(2):209-25. PubMed ID: 17064802
[TBL] [Abstract][Full Text] [Related]
32. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
[TBL] [Abstract][Full Text] [Related]
33. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
Lemberg KM; Vornov JJ; Rais R; Slusher BS
Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
[TBL] [Abstract][Full Text] [Related]
34. In vitro PET evaluations in lung cancer cell lines.
Xing T; Wu F; Brodin O; Fasth KJ; Långström B; Bergström M
Anticancer Res; 2000; 20(3A):1375-80. PubMed ID: 10928046
[TBL] [Abstract][Full Text] [Related]
35. Synthesis of [76Br]bromofluorodeoxyuridine and its validation with regard to uptake, DNA incorporation, and excretion modulation in rats.
Lu L; Bergström M; Fasth KJ; Langström B
J Nucl Med; 2000 Oct; 41(10):1746-52. PubMed ID: 11038007
[TBL] [Abstract][Full Text] [Related]
36. In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker.
Bergström M; Lu L; Fasth KJ; Wu F; Bergström-Pettermann E; Tolmachev V; Hedberg E; Cheng A; Långström B
J Nucl Med; 1998 Jul; 39(7):1273-9. PubMed ID: 9669410
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
